RxDoctor Payments Data

Carlos Nieves, MD

Cardiovascular Disease · Bayamon, PRNPI 1770632572

Payments from drug & device makers

$657in general payments, 2019–2025

Across 19 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$227
  • Chiesi USA, Inc.$105
  • United Therapeutics Corporation$100
  • AstraZeneca$63
  • Novartis$49
  • PBG Puerto Rico LLC$42
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$58289%
  • Gifts$7511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$657 in reported general payments places this provider in the 20th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,474
Medicare patients
27
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$66,554
EntrestoSacubitril/Valsartan39$52,796
XareltoRivaroxaban24$26,399
BrilintaTicagrelor25$20,987
Metoprolol Succinate147$4,031
Candesartan Cilexetil22$2,347
Atorvastatin Calcium148$2,169
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide39$1,647
SynthroidLevothyroxine Sodium13$1,458
Losartan Potassium89$1,338
Ezetimibe35$1,105
ClopidogrelClopidogrel Bisulfate55$1,066
Amiodarone Hcl19$1,054
Fenofibrate21$1,053
Doxazosin Mesylate34$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$49$52,79639 claims
Johnson & JohnsonXarelto$20$26,39924 claims
AstraZenecaBrilinta$63$20,98725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →